Online inquiry

IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1271MR)

This product GTTS-WQ1271MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Glioblastoma multiforme (GBM) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1271MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11049MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MCLA-128
GTTS-WQ7232MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ15018MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ3107MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA APN311
GTTS-WQ3043MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ8480MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HTI-1088
GTTS-WQ15479MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA UCB-0107
GTTS-WQ3482MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BA1126
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW